ILInna N. Lavrentieva

Inna N. Lavrentieva

*This is an algorithmically generated author record based on publicly available information.

Inna N. Lavrentieva has a total of 119 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Approaches to the treatment of ischemic stroke in children

    by A. A. Kuznetsova, I. O. Shchederkina, L. E. Larina, P. V. Svirin, A. E. Kessel, M. I. Stepanenko, I. N. Lavrentieva, S. A. Tulupova, A. A. Tsaturova, A. M. Kozlova, et al.

    Background. There are no standardised protocols for the treatment of ischaemic stroke in children to date. Objective. To evaluate outcomes in patients with a confirmed diagnosis of acute arterial ischaemic stroke who received antithrombotic therapy at the Centre for Cerebrovascular Diseases in Children and Adolescents (the Centre) based at the Morozovskaya Children's City Clinical Hospital of the Moscow City Health Department. Materials and methods. A single-centre retrospective study was conducted, including 145 patients with confirmed arterial ischaemic stroke between 2019 and 2023. All patients underwent a comprehensive examination, including assessment of neurological status using the PedNIHSS scale, neuroimaging (MRI with angiography), extensive laboratory testing of the haemostasis system, and cardiac and vascular evaluation. Aetiological classification was performed according to the CASCADE criteria. Four antithrombotic therapy regimens were used: anticoagulant therapy with unfractionated heparin with or without transition to low molecular weight heparin, or monotherapy with low molecular weight heparin – 21 patients (14.5%); monotherapy with acetylsalicylic acid – 25 patients (17.2%); combination therapy with transition from heparins to acetylsalicylic acid within 3-6 months – 99 patients (68.3%). Doses were adjusted based on anti-Xa activity monitoring. Systemic thrombolysis with alteplase was performed in 17 patients (11.7%). Long-term outcomes were assessed at a median of 41 months using the modified Rankin Scale and the PSOM scale. Statistical analysis was performed using non-parametric methods. Results. In this cohort the median age was 4 years 5 months; 64.8% were boys. Aetiology remained undetermined in 21.4% of cases; arteriopathies were identified in 18.6%, and multifactorial genesis in 15.9%. Thrombolytic therapy was administered to 17 patients (11.7%). No statistically significant differences in long-term outcomes were found between the different antithrombotic therapy regimens. Recurrent stroke was recorded in 8.3% of patients. Post-stroke epilepsy developed in 9.3% and was associated with more severe neurological deficit (p < 0.05). In patients with cardioembolic stroke in the perioperative period, a significant decrease in antithrombin III activity (p = 0.005) and protein C activity (p = 0.006) was observed. In the group of patients with post-stroke epilepsy, long-term outcomes were significantly worse than in patients without epilepsy, which likely indicates a negative impact of epileptogenesis on neuroplasticity processes. Thrombolytic therapy was not associated with severe bleeding or recurrences. However, its benefits require further study due to the lack of randomisation. Conclusion. Anticoagulants, antiplatelet agents, and thrombolysis are used in the treatment of acute arterial ischaemic stroke in children, but to date, no proven advantages of any specific treatment regimen for arterial ischaemic stroke in children have been established.

  • Open Access

    A Rare Variant of Mitochondrial Pathology in a Child: A Case Report of Pearson Syndrome

    by Valeriya A. Evdokimova, Tamara Yu. Kuptsova, Inna N. Lavrentieva, Lyubov E. Larina, Irina A. Maksimova

    Background . Pearson syndrome (PS) is an exceptionally rare mitochondrial disorder of childhood, characterized by marked clinical polymorphism, which often leads to diagnostic errors and delayed correct diagnosis. The presented clinical case is intended to draw clinicians’ attention to the early hematological manifestations of the syndrome and to highlight the complexity of differential diagnosis in neonates and infants. Case Report. From the first day of life, the child was found to have hyporegenerative normocytic anemia (hemoglobin 90 g/L on day 2 of life), which required red blood cell transfusions. Subsequently, the development of pancytopenia (leukocytes down to 2 × 10 9 /L, platelets down to 93 × 10 9 /L) and episodes of severe hyperlactatemia — up to 11.2 mmol/L — were noted. Morphological examination of the bone marrow revealed vacuolization of cellular elements and moderate hypocellularity without narrowing of the erythroid lineage, which led to suspicion of PS. Molecular genetic testing confirmed the presence of a large deletion of mitochondrial DNA (~5000 bp) in a homoplasmic state, thus verifying PS. Symptomatic therapy was administered, including blood component transfusions, high-dose intravenous immunoglobulin, and antibacterial treatment, which resulted in temporary stabilization of blood counts. Conclusion . The presented case report underscores the importance of including mitochondrial disorders early in the diagnostic workup of hyporegenerative normochromic normocytic anemia with elevated lactate levels in infants, demonstrates the need for a multidisciplinary approach, and highlights the necessity of timely genetic testing.

  • Late diagnosis of Wilson’s disease in children: case series

    by T.A. Skvortsova, G.V. Volynets, K.A. Khasanova, E.S. Korochkina, D.A. Skobeev, A.V. Nikitin, I.N. Lavrentyeva, E.V. Ageenkova, D.YU. Nikolaeva, Yu.V. Romanova, et al.

    Wilson’s disease is a rare hereditary disorder related to copper metabolism dysfunction, which can lead to liver damage, neurological impairments, and other organ complications. Early diagnosis in children is challenging due to non-specific symptoms, often resulting in the development of complications such as liver cirrhosis. Objective. To present clinical cases of late diagnosis of Wilson’s disease in children and to describe the difficulties physicians face when diagnosing the disease at advanced stages. Clinical case. The article presents three clinical cases of children diagnosed with Wilson’s disease at over 15 years of age. All patients exhibited cirrhosis-related complications, including thrombocytopenia, esophageal varices, anemia, and biochemical abnormalities. The diagnosis was confirmed in all patients through laboratory and genetic testing. Conclusion. Late diagnosis of Wilson’s disease complicates treatment and often necessitates liver transplantation. Early diagnosis is crucial for timely initiation of pharmacological therapy and the prevention of serious complications. These clinical cases highlight the importance of regular screening in children suspected of having Wilson’s disease, especially in those with cirrhosis or other liver dysfunctions, to improve treatment outcomes.

  • Intensive care of intracranial hemorrhages in infants: а 5-year single-center experience

    by A. E. Tsygankov, D. V. Gorokhov, I. O. Shchederkina, M. I. Livshits, I. N. Lavrentieva, D. A. Tkacheva, E. E. Petryaykina, D. Y. Ovsyannikov, Z. U. Zohidov, G. E. Chmutin, et al.

    Introduction: Prevention of hemorrhagic disease in newborns (HDN) in recent years has significantly reduced the number of intracranial hemorrhages (ICH) associated with these pathologies and the most common etiological cause of hemorrhagic stroke in infants. However, the issues of intensive therapy for intracranial hemorrhages in young patients of various etiologies didn’t lose their relevance.Objective: Study of the peculiarities of approaches to intensive care in children with ICH. Material and methods: The medical documentation of 35 patients aged 21 days to 4 months with ICH of various etiologies from 2017 to 2021 was analyzed. Results: Due to the severity of their conditions, 83 % of patients required mechanical ventilation. In our case series of 29 children with vitamin K-deficient coagulopathy the mortality was 3.4 %. Cerebral vasospasm developed in 57.1 % of intracranial hemorrhage cases. The duration of stay in the intensive care unit and the duration of mechanical ventilation, in addition to the severity of the condition at admission, hemorrhagic shock and neurological deficit, were influenced by cerebral vasospasm and convulsive syndrome. Conclusion: A retrospective analysis of the results of the treatment of neonates with intracranial hemorrhages caused by a late form of HDN allowed us to identify factors affecting the severity of the condition and outcomes. Since the incidence of this severe pathology is relatively low, and the literature data are contradictory, the personal experience of each hospital is important.


  • Open Access

    Statistically significant improvement in hemophilia A control: a retrospective analysis of the effectiveness and safety of emicizumab in children with severe and inhibitor forms of hemophilia A

    by V. Yu. Petrov, I. N. Lavrentyeva, V. V. Vdovin, P. V. Svirin

    Hemophilia A presents a serious problem, especially in its severe and inhibitor forms, leading to severe bleeding and complications. The importance of studying the effectiveness and safety of new treatment approaches, particularly emicizumab, is undeniable for improving the quality of life of patients.   Aim: to evaluate the effectiveness and safety of emicizumab in the prevention of bleeding in children with severe and inhibitor forms of hemophilia A. Ethical approval was not required since the study only involved the use of generalized retrospective data obtained during routine clinical practice. All data were depersonalized. A retrospective analysis of medical records of 45 children treated at the Morozov Children's Hospital from 2006 to 2022 was carried out. The study included two cohorts: those with severe hemophilia A and those with inhibitor forms. The analysis included an assessment of the frequency of bleeding and hemarthrosis episodes, hospital admissions, and adverse reactions. The analysis included data from 45 patients with hemophilia A who underwent treatment with emicizumab from 2018 to 2022. Of these, 30 children had a severe form of hemophilia A, and 15 had an inhibitor form. The median follow-up period for a severe form was 17 months, ranging from 12 to 23 months, while for an inhibitor form, it was 32 months, with a range of 11 to 51 months. In the group with severe hemophilia A, a statistically significant (p < 0.001) reduction in the frequency of all types of bleeding was observed: 96.7 % of children had no episodes of hemarthrosis during emicizumab therapy, compared to 46.7 % of patients previously treated with FVIII concentrates. No spontaneous hemarthrosis was registered. Similar results were observed in the group with an inhibitor form of hemophilia A: 93.3 % of children had no hemarthrosis episodes while using emicizumab compared to 13.3% during previous treatment with bypassing agents. Over the entire follow-up period, there were 3 bleedings in the cohort of children with severe hemophilia A and 1 bleeding in the cohort of children with inhibitor hemophilia A. Prior to the use of emicizumab, out of 391 bleeding episodes that occurred in 45 children, 218 were spontaneous. Adverse events were recorded in 7 children, manifesting as erythema at the injection site after the first or first and second emicizumab injections and resolving spontaneously. There were no other adverse events; 90 % of children with severe hemophilia A and 73.3 % of children with inhibitor hemophilia A did not report any adverse events during the use of emicizumab. Emicizumab demonstrates high effectiveness and safety in the treatment of children with severe hemophilia A, both with and without inhibitors. The drug significantly reduces the frequency of bleeding episodes and improves the quality of life of patients.

  • THROMBOLYTIC THERAPY IN PEDIATRIC PRACTICE: A BIBLIOGRAPHICAL REVIEW (PART 2)

    by Moscow Morozov Children’s City Clinical Hospital, P.V. Svirin, L.E. Larina, I.N. Lavrentyevа

    Part 2 of the Article represents published data dedicated to the thrombolytic therapy (TT) for thrombosis of various localizations in children. Options for dosing and methods of thrombolytic therapy are considered. Indications and contraindications for this method of treatment are described. information on thrombolytic therapy in newborns is provided as well. Part 1 of the Article is available at https://doi.org/10.24110/0031-403X-2023-102-3-145-150: P.V. Svirin, L.E. Larina, I.N. Lavrentyeva. Thrombolytic therapy in pediatric practice (Part 1). Pediatria n.a. G.N. Speransky. 2023; 102 (3): 145-150. DOI: 10.24110/0031-403X-2023-102-3-145-150.

  • THROMBOLYTIC THERAPY IN PEDIATRIC PRACTICE (PART 1)

    by Moscow Morozov Children’s City Clinical Hospital, P.V. Svirin, L.E. Larina, I.N. Lavrentyevа

    Thromboses in children represent the serious pathology that can lead to disability and even death of a pediatric patient. At certain localizations of thrombosis, the most rapid restoration of vascular patency (reperfusion) becomes prognostically significant. The most accessible method for reperfusion is drug therapy, in which a drug is injected into the patient's blood, which in its turn significantly accelerates the process of fibrinolysis, i.e., thrombolytic therapy (TT). The purpose of this bibliographical review was to familiarize physicians, especially pediatricians with the place of TT in modern clinical practice. The article represents bibliographical review of published works for over 50 years (since 1966). Authors have used both domestic Russian resources and the PUBMED database. Articles were selected based on the relevance. Statistical analysis was not performed. A review and analysis of bibliographical data on the modern use of TT in pediatric practice is presented. Preference was given to the most modern publications containing analytical information with full text available both pro bono and online. Authors emphasize pediatric practitioners’ attention on the fact that TT at the current level of knowledge is a fairly effective and predictable method for rapid reperfusion.

  • Open Access

    Laparoscopic appendectomy in a child with hemophilia A with inhibitors receiving prophylactic treatment with emicizumab

    by I. N. Lavrentyeva, V. V. Vdovin, V. Yu. Petrov, P. A. Mordvin, T. V. Shevchenko, I. Yu. Kopylov, O. A. Tiganova, E. V. Kumirova, M. Yu. Kozlov

    Surgeries in patients treated prophylactically with emicizumab (including surgical procedures with a high risk of postoperative bleeding) are not associated with higher risks or technical difficulties compared with operations in patients receiving standard replacement therapy. On the contrary, the presence of emicizumab in the blood and its maintenance of permanent basic hemostasis allow for the reduction of doses and infusion time of bypassing agents. Patients undergoing surgical procedures with a high risk of postoperative bleeding require an additional hemostatic treatment during the first two or three days after the surgery. Then the duration of hemostatic treatment should be determined individually. We recommend the use of recombinant activated factor VII for the prevention/control of postoperative bleeding in patients with hemophilia A with inhibitors who are currently receiving emicizumab or have received it in the past 6 months. If treatment with anti-inhibitor coagulant complex is required, the daily dose should not exceed 100 units/kg. Here we report the first case of laparoscopic appendectomy in an 8-year-old child with hemophilia A with inhibitors receiving prophylactic treatment with emicizumab. The patient's parents gave their consent to the use of their child's data, including photographs, for research purposes and in publications.

  • RESULTS OF OPEN, PROSPECTIVE, MULTICENTER, NON-COMPARATIVE STUDY OF NONACOG ALPHA PHARMACOKINETICS, EFFICACY AND SAFETY IN CHILDREN AGED 2–12 YEARS WITH SEVERE AND MODERATE HEMOPHILIA В

    by Saint Petersburg Saint Petersburg City Polyclinic No. 37, T.A. Andreeva, V.V. Lebedev, Krasnodar Krasnodar Krai Regional Children'S Clinical Hospital, V.V. Vdovin, Moscow Morozov Children’s City Clinical Hospital, M.A. Timofeeva, I.L. Davydkin, I.A. Lavrichenko, O.A. Krasheninnikova, et al.

    The aim of the study was to evaluate the efficacy, safety and pharmacokinetics of nonacog alfa (Innonafactor) in children aged 2 to 12 years with hemophilia B. Materials and methods: 15 patients (7.7±2.5 years ) were included in an open, multicenter, prospective, non-comparative clinical trial, of whom 12 were aged 6 to 12 years and 3 were aged 2 to 6 years. The efficacy of the drug was assessed against the background of the introduction of 45±10 IU/kg 2 times a week with an interval of 72–96 hours, the safety was assessed by the frequency and nature of adverse reactions. Results: 5 (22%) spontaneous and 18 (78%) post-traumatic bleedings were registered. The mean number of spontaneous bleeding within 72 hours after administration of nonacog alfa was 2±1.4. The average prophylactic dose was 47.74±6.47 IU/kg (Me 48.2 IU/kg). An average of 2.2±2.1 injections was required to stop a bleeding episode. 19 adverse events have been reported that are not related to nonacog alfa. Conclusion: the obtained data indicate the efficacy and safety of nonacog alfa in the study group of patients. Thus, the data obtained indicate the efficacy and safety of Innonafactor drug both for prophylactic treatment and for the relief of bleeding in patients aged 2 to 12 years with severe and moderate hemophilia B.


  • Open Access

    Laparoscopic appendectomy in a child with hemophilia A with inhibitors receiving prophylactic treatment with emicizumab

    by I. N. Lavrentyeva, V. V. Vdovin, V. Yu. Petrov, P. A. Mordvin, T. V. Shevchenko, I. Yu. Kopylov, O. A. Tiganova, E. V. Kumirova, M. Yu. Kozlov

    Surgeries in patients treated prophylactically with emicizumab (including surgical procedures with a high risk of postoperative bleeding) are not associated with higher risks or technical difficulties compared with operations in patients receiving standard replacement therapy. On the contrary, the presence of emicizumab in the blood and its maintenance of permanent basic hemostasis allow for the reduction of doses and infusion time of bypassing agents. Patients undergoing surgical procedures with a high risk of postoperative bleeding require an additional hemostatic treatment during the first two or three days after the surgery. Then the duration of hemostatic treatment should be determined individually. We recommend the use of recombinant activated factor VII for the prevention/control of postoperative bleeding in patients with hemophilia A with inhibitors who are currently receiving emicizumab or have received it in the past 6 months. If treatment with anti-inhibitor coagulant complex is required, the daily dose should not exceed 100 units/kg. Here we report the first case of laparoscopic appendectomy in an 8-year-old child with hemophilia A with inhibitors receiving prophylactic treatment with emicizumab. The patient's parents gave their consent to the use of their child's data, including photographs, for research purposes and in publications.